FDA safety update · November 2026
Lose the weight. Keep everything else.
The FDA added a warning about a rare eye condition to every GLP-1. Here's how rare it is, what the evidence shows and the one symptom to know.
Medically reviewed by Mark Nessim, MD, board-certified anesthesiologist · Last updated
Who publishes this: Habthera Nutrition, which makes ASP-1, a protein supplement. Where our product appears it is labeled as ours. Editorial policy.
The short answer
On November 9, 2026, the FDA said it is requiring every GLP-1 medicine to add a warning about a possible increased risk of NAION, a rare condition that can cause sudden vision loss, to the Warnings and Precautions section of its label.[1][2] It covers semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), orforglipron (Foundayo) and the older drugs in the class.[2]
It is a label warning, not a recall and not a restriction on who can take these drugs.[3] The practical change for you is one rule: sudden vision loss is an emergency. Get an eye exam the same day.
What NAION is
NAION stands for non-arteritic anterior ischemic optic neuropathy. Blood flow to the front of the optic nerve drops, and the nerve is damaged.[4] It usually affects one eye. The vision loss is typically painless and sudden, and people often notice it on waking. It can be partial, like a shadow over the top or bottom half of the view, and it can be permanent.[5]
It was a known condition long before GLP-1s. The usual risk factors include a small, crowded optic disc, diabetes, high blood pressure, sleep apnea and older age, which overlap heavily with the people most likely to be prescribed a GLP-1. That overlap is one reason the evidence has been hard to read.
What the FDA found
For scale: in 2025, the European Medicines Agency's safety committee classed NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people taking it for at least a year.[4][6]
What to do
Tell the anesthesia team you take a GLP-1, for the stomach-emptying reasons in our procedure guide. If you have had NAION before, mention that too. It is part of the history an anesthesiologist wants before long or prone-position operations.
Yes. On November 9, 2026 the FDA required all GLP-1 receptor agonist medicines, including semaglutide, tirzepatide and orforglipron, to add a warning about a potential increased risk of NAION, a rare cause of sudden vision loss, to the Warnings and Precautions section of their labels.
Do not stop on your own. The warning does not restrict who can take these drugs. Talk to your prescriber, especially if you have had NAION before, and get a same-day eye exam if you notice sudden vision loss.
It is rare. In 2025 the European Medicines Agency estimated it may affect up to 1 in 10,000 people taking semaglutide for at least a year. In the trial data the FDA reviewed, there were 10 probable cases among GLP-1 users and 5 among placebo users across 126 trials.
Sudden, usually painless vision loss in one eye, often noticed on waking. It can affect the upper or lower half of vision or look like a shadow or blur. It needs a same-day eye exam.
Keep reading